| Literature DB >> 25499761 |
Margherita Bodini1, Chiara Ronchini1, Luciano Giacò2, Anna Russo2, Giorgio E M Melloni1, Lucilla Luzi3, Domenico Sardella4, Sara Volorio4, Syed K Hasan5, Tiziana Ottone6, Serena Lavorgna6, Francesco Lo-Coco6, Anna Candoni7, Renato Fanin7, Eleonora Toffoletti7, Ilaria Iacobucci8, Giovanni Martinelli8, Alessandro Cignetti9, Corrado Tarella9, Loris Bernard10, Pier Giuseppe Pelicci11, Laura Riva1.
Abstract
The analyses carried out using 2 different bioinformatics pipelines (SomaticSniper and MuTect) on the same set of genomic data from 133 acute myeloid leukemia (AML) patients, sequenced inside the Cancer Genome Atlas project, gave discrepant results. We subsequently tested these 2 variant-calling pipelines on 20 leukemia samples from our series (19 primary AMLs and 1 secondary AML). By validating many of the predicted somatic variants (variant allele frequencies ranging from 100% to 5%), we observed significantly different calling efficiencies. In particular, despite relatively high specificity, sensitivity was poor in both pipelines resulting in a high rate of false negatives. Our findings raise the possibility that landscapes of AML genomes might be more complex than previously reported and characterized by the presence of hundreds of genes mutated at low variant allele frequency, suggesting that the application of genome sequencing to the clinic requires a careful and critical evaluation. We think that improvements in technology and workflow standardization, through the generation of clear experimental and bioinformatics guidelines, are fundamental to translate the use of next-generation sequencing from research to the clinic and to transform genomic information into better diagnosis and outcomes for the patient.Entities:
Mesh:
Year: 2014 PMID: 25499761 PMCID: PMC4304104 DOI: 10.1182/blood-2014-05-576157
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113